Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacodynamics of Tegoprazan vs Dexlansoprazole Evening Dosing
NCT03043521Phase 1Completed
- Sponsor
- HK inno.N Corporation
- Start
- May 2015
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tegoprazan in gastroesophageal reflux disease (GERD) (4 arms), sponsored by HK inno.N Corporation. Primary endpoint: Time gastric pH > 4 at 24 hours. Started May 2015; status: completed.
02
Drugs
tegoprazan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT03043521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03043521.